Table 1.
Overview of studies including conventional tumor markers as predictive biomarkers for chemotherapy response in pancreatic cancer patients.
| Author | Year of Publication | Number of Patients | Stage of Disease | Treatment | Biomarker |
|---|---|---|---|---|---|
| Gogas [40] | 1998 | 39 | LAPC (n = 21) + metastatic (n = 18) | 5-FU + cisplatin + epirubicine | CA19-9 |
| Halm [41] | 2000 | 36 | LAPC + metastatic | Gemcitabine | CA19-9 |
| Stemmler [43] | 2003 | 77 | LAPC + metastatic | Gemcitabine + cisplatin | CA19-9 |
| Ali [42] | 2007 | 18 | LAPC + metastatic | Gemcitabine | CA19-9 |
| Wong [44] | 2008 | 75 | Metastatic | Gemcitabine + cisplatin (n = 41) Gemcitabine + cisplatin + bevacizumab (n = 34) |
CA19-9 |
| An [38] | 2009 | 61 | LAPC + metastatic | Gemcitabine Gemcitabine + oxaliplatin Gemcitabine + 5FU/CF |
CA19-9 |
| Koom [37] | 2009 | 69 | Borderline resectable + LAPC | Gemcitabine + radiation Paclitaxel + radiation |
CA19-9 |
| Yoo [39] | 2011 | 84 | LAPC | Radiation + 5-FU (n = 53) Radiation + capecitabine (n = 31) |
CA19-9 |
| Tsutsumi [46] | 2012 | 90 | LAPC + metastatic | Gemcitabine | CA19-9 SPAN-1 |
| Boeck [36] | 2013 | 68 | LAPC + metastatic + recurrence | Gemcitabine Gemcitabine + erlotinib Gemcitabine + everolimus Gemcitabine + axitinib Gemcitabine + WX-671 Capecitabine Capecitabine + erlotinib Nab-paclitaxel |
CA19-9 CEA |
| Azzariti [47] | 2016 | 27 | Metastatic | FOLFIRINOX (n = 21) Gemcitabine + nab-paclitaxel (n = 6) |
CA19-9 |
| Chiorean [45] | 2016 | 454 | Metastatic | Gemcitabine (n = 202) Gemcitabine + nab-paclitaxel (n = 252) |
CA19-9 |
| Robert [48] | 2017 | 160 | Metastatic | FOLFIRINOX (n = 85) Gemcitabine (n = 75) |
CA19-9 |
LAPC = locally advanced pancreatic cancer, CA19-9 = carbohydrate antigen 19-9, CEA = carcinoembryonic antigen.